Tarcocimab Tedromer

Summary

Tarcocimab Tedromer (CHEMBL5095154) is a phase-3 clinical-stage antibody drug conjugate; indicated across 3 conditions including wet macular degeneration and diabetic retinopathy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095154
Name	Tarcocimab Tedromer
Type	Antibody drug conjugate
Max phase	3

Also known as: Ksi-301, KSI-301, OG-1953, OG1953, Tarcocimab tedromer, Tarcocimab tedromere, Tarcocimab tedromero, TARCOCIMAB TEDROMER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
wet macular degeneration	2	MONDO:0005417	EFO:0004683
diabetic retinopathy	1	MONDO:0005266	EFO:0003770
vascular disorder	1	MONDO:0005385	EFO:0004264

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	6
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06556368	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT04049266	PHASE2/PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
NCT04592419	PHASE3	COMPLETED	A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
NCT04603937	PHASE3	TERMINATED	A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04611152	PHASE3	TERMINATED	A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04964089	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
NCT05066230	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
NCT03790852	PHASE1	TERMINATED	Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).